Literature DB >> 29189878

[Quality indicators for colon cancer surgery : Evidence-based development of a set of indicators for the outcome quality].

J Hardt1, H-J Buhr2, C Klinger2, S Benz3, K Ludwig4, J Kalff5, S Post6.   

Abstract

BACKGROUND: Quality assessment in surgery is gaining in importance. Although sporadic recommendations for quality indicators (QI) in oncological colon surgery can be found in the literature, these are usually not systematically derived from a solid evidence base. Moreover, reference ranges for QI are unknown.
OBJECTIVE: The aim of this initiative was the development of evidence-based QI for oncological colon resections by an expert panel invited by the German Society of General and Visceral Surgery (DGAV). Reference ranges from the literature and reference values from the Study, Documentation, and Quality Center (StuDoQ)|Colon Cancer Register were compared in order to deduce recommendations which are tailored to the German healthcare system.
RESULTS: Based on the most recent scientific evidence and agreed by expert consensus, five QI for oncological colon surgery were defined and evaluated according to the QUALIFY tool. Mortality, MTL30 (mortality, transfer to another acute care hospital, or length of stay ≥30 days), anastomotic leakage requiring reintervention, surgical site infections necessitating reopening of the wound and ≥12 lymph nodes in the specimen qualified as QI owing to their relevance, scientific nature, and practicability. Based on the results of the systematic literature search and the statistical analysis of the StuDoQ|Colon Cancer Register, preliminary reference values are proposed for each QI.
CONCLUSION: The presented set of QI seems appropriate for quality assessment of oncological colon surgery in the context of the German healthcare system. The validity of the QI and the reference values must be reviewed within the framework of their implementation. The StuDoQ|Colon Cancer Register provides a suitable infrastructure for collecting clinical data for quality assessment and risk adjustment.

Entities:  

Keywords:  Colon cancer; Colorectal cancer register; Reference values; Risk adjustment

Mesh:

Year:  2018        PMID: 29189878     DOI: 10.1007/s00104-017-0559-0

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  50 in total

1.  Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial.

Authors:  Ruben Veldkamp; Esther Kuhry; Wim C J Hop; J Jeekel; G Kazemier; H Jaap Bonjer; Eva Haglind; Lars Påhlman; Miguel A Cuesta; Simon Msika; Mario Morino; Antonio M Lacy
Journal:  Lancet Oncol       Date:  2005-07       Impact factor: 41.316

2.  Evaluating the validity of quality indicators for colorectal cancer care.

Authors:  Gea A Gooiker; Nikki E Kolfschoten; Esther Bastiaannet; Cornelis J H van de Velde; Eric H Eddes; Erwin van der Harst; Theo Wiggers; Frits R Rosendaal; Rob A E M Tollenaar; Michel W J M Wouters
Journal:  J Surg Oncol       Date:  2013-09-20       Impact factor: 3.454

3.  Laparoscopic surgery in patients with colon cancer: a population-based analysis.

Authors:  Stefan Benz; Hagen Barlag; Michael Gerken; Alois Fürst; Monika Klinkhammer-Schalke
Journal:  Surg Endosc       Date:  2016-10-04       Impact factor: 4.584

4.  Short-term outcomes after complete mesocolic excision compared with 'conventional' colonic cancer surgery.

Authors:  C A Bertelsen; A U Neuenschwander; J E Jansen; A Kirkegaard-Klitbo; J R Tenma; M Wilhelmsen; L A Rasmussen; L V Jepsen; B Kristensen; I Gögenur
Journal:  Br J Surg       Date:  2016-01-18       Impact factor: 6.939

5.  Association of Comorbidity with Anastomotic Leak, 30-day Mortality, and Length of Stay in Elective Surgery for Colonic Cancer: A Nationwide Cohort Study.

Authors:  Peter-Martin Krarup; Andreas Nordholm-Carstensen; Lars Nannestad Jorgensen; Henrik Harling
Journal:  Dis Colon Rectum       Date:  2015-07       Impact factor: 4.585

Review 6.  Surgery along the embryological planes for colon cancer: a systematic review of complete mesocolic excision.

Authors:  Nikolaos Gouvas; Christos Agalianos; Kleio Papaparaskeva; Aristotelis Perrakis; Werner Hohenberger; Evaghelos Xynos
Journal:  Int J Colorectal Dis       Date:  2016-07-28       Impact factor: 2.571

7.  Survival in stage III colon cancer is independent of the total number of lymph nodes retrieved.

Authors:  Vassiliki L Tsikitis; David L Larson; Bruce G Wolff; Gregory Kennedy; Nancy Diehl; Rui Qin; Eric J Dozois; Robert R Cima
Journal:  J Am Coll Surg       Date:  2009-01       Impact factor: 6.113

8.  Identification of 12 or more lymph nodes in resected colon cancer specimens as an indicator of quality performance.

Authors:  Robert O Dillman; Kenneth Aaron; F Scott Heinemann; Stephanie E McClure
Journal:  Cancer       Date:  2009-05-01       Impact factor: 6.860

9.  Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer?

Authors:  Jiping Wang; Mahmoud Kulaylat; Howard Rockette; James Hassett; Ashwani Rajput; Kelli Bullard Dunn; Merril Dayton
Journal:  Ann Surg       Date:  2009-04       Impact factor: 12.969

10.  Significant Individual Variation Between Pathologists in the Evaluation of Colon Cancer Specimens After Complete Mesocolic Excision.

Authors:  Ditte Louise E Munkedal; Søren Laurberg; Rikke Hagemann-Madsen; Katrine J Stribolt; Søren R P Krag; Philip Quirke; Nicholas P West
Journal:  Dis Colon Rectum       Date:  2016-10       Impact factor: 4.585

View more
  2 in total

1.  [Case load and quality indicators in the treatment of abdominal aortic aneurysms].

Authors:  Y Carmen Ahmadzadeh; Th Schmitz-Rixen; D Böckler; R T Grundmann
Journal:  Chirurg       Date:  2021-09       Impact factor: 0.955

2.  Safety of anastomoses in colorectal cancer surgery in octogenarians: a prospective cohort study with propensity score matching.

Authors:  Kai S Lehmann; Carsten Klinger; Johannes Diers; Heinz-Johannes Buhr; Christoph-Thomas Germer; Armin Wiegering
Journal:  BJS Open       Date:  2021-11-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.